Outcomes of acute coronary syndrome (ACS) patients undergoing percutaneous coronary
intervention (PCI) have been significantly improved with the use of potent P2Y 12 receptor …

Aims The value of platelet function testing (PFT) in predicting clinical outcomes and guiding
P2Y12-inhibitor treatment is uncertain. In a pre-specified sub-study of the TROPICAL-ACS …

Objectives: This study sought to evaluate the impact of treatment with prasugrel and high-
dose clopidogrel on the basis of platelet function testing in patients with acute coronary …

Dual antiplatelet therapy, consisting of aspirin and a P2Y12 receptor inhibitor, has
dramatically reduced the incidence of atherothrombotic events for patients with acute …

Background Current guidelines recommend potent platelet inhibition with prasugrel or
ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous …

Introduction There is compelling evidence supporting the association between high on-
treatment platelet reactivity (HPR) and low on-treatment platelet reactivity (LPR) to …

Background When considering antiplatelet therapy for acute coronary syndrome (ACS), it is
essential to balance benefits (less thrombotic/ischaemic events) versus bleeding risks …

Although clopidogrel is more effective in preventing thrombotic complications than aspirin
alone in a broad spectrum of patients with ischemic heart disease, many of its limitations …

Although some observational studies reported that the measured level of P2Y12-inhibition is
predictive for thrombotic events, the clinical and economic benefit of incorporating PFT to …

Current guidelines recommend that patients with acute coronary syndrome (ACS)
undergoing percutaneous coronary intervention (PCI) should receive a loading dose of a …